Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
25 March 2013 |
Main ID: |
EUCTR2009-015754-38-DK |
Date of registration:
|
27/04/2010 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
An extension trial to NN1250-3579 comparing safety and efficacy of NN1250 plus
OAD(s) with insulin glargine plus OAD(s) in type 2 diabetes - BEGIN™: ONCE LONG
|
Scientific title:
|
An extension trial to NN1250-3579 comparing safety and efficacy of NN1250 plus
OAD(s) with insulin glargine plus OAD(s) in type 2 diabetes - BEGIN™: ONCE LONG |
Date of first enrolment:
|
12/05/2010 |
Target sample size:
|
552 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-015754-38 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes
Randomised: no
Open: yes
Single blind: no
Double blind: no
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: no
Other: no
|
Phase:
|
|
|
Countries of recruitment
|
Austria
|
Belgium
|
Czech Republic
|
Denmark
|
Finland
|
France
|
Germany
|
Spain
|
Contacts
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Informed consent obtained before any trial-related activities. (Extension trial-related activities are defined as any procedure that would not have been performed during normal management of the subject or as part of the main trial NN1250-3579.)
2. The subject must have completed the 52 week treatment period in trial NN1250-3579. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria: 1. Previous participation in this trial. Participation is defined as participation in any Visit 43 related procedures.
2. Females of childbearing potential who are pregnant, breast-feeding, or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practise [for Germany: implants, injectables, combined oral contraceptives, hormonal IUD, sexual abstinence or vasectomised partner].
3. Anticipated change in concomitant medication known to interfere significantly with glucose metabolism, such as systemic corticosteroids, beta-blockers, MAO inhibitors.
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Type 2 diabetes MedDRA version: 14.0
Level: PT
Classification code 10067585
Term: Type 2 diabetes mellitus
System Organ Class: 10027433 - Metabolism and nutrition disorders
|
Intervention(s)
|
Product Name: NN1250 Product Code: NN1250 Pharmaceutical Form: Solution for injection Current Sponsor code: NNC 0100-0000-0454 Concentration unit: U/ml unit(s)/millilitre Concentration type: equal Concentration number: 100-
Trade Name: Lantus Pharmaceutical Form: Solution for injection INN or Proposed INN: Insulin glargine CAS Number: 160337-95-1 Concentration unit: U/ml unit(s)/millilitre Concentration type: equal Concentration number: 100-
|
Primary Outcome(s)
|
Primary end point(s): • Number of treatment emergent adverse events with an onset on or after the first day of exposure to randomised trial drug and no later than 7 days after last exposure to randomised trial drug • Number of severe and minor treatment emergent hypoglycaemic episodes with an onset on or after the first day of exposure to randomised trial drug and not later than 7 days after last exposure to randomised trial drug • Change from baseline in insulin antibodies after 104 weeks of treatment
|
Secondary Objective: The secondary objective is to compare the efficacy between NN1250 and insulin glargine after 104 weeks of treatment, in terms of the listed efficacy assessments from which endpoints will be calculated: • HbA1c (central laboratory) • Fasting plasma glucose (FPG) measured at a central laboratory • 9-point self measured plasma glucose (SMPG) profile • Self measured plasma glucose for dose adjustments • Patient Reported Outcome (PRO) Questionnaire
|
Main Objective: The primary objective is to investigate the long-term safety and tolerability of NN1250. This is done by comparing NN1250 to insulin glargine after 104 weeks of treatment (52 weeks of treatment in NN1250-3579 plus 52 weeks of treatment in this extension trial) in terms of the listed safety assessments from which endpoints will be calculated: • Adverse events • Hypoglycaemic episodes • Clinical evaluation • Laboratory assessments • Body weight • Insulin dose
|
Secondary ID(s)
|
2009-015754-38-FR
|
NN1250-3643
|
Source(s) of Monetary Support
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|